Profusa, Inc. (NASDAQ:PFSA) Sees Large Increase in Short Interest

Profusa, Inc. (NASDAQ:PFSA) was the recipient of a significant increase in short interest in June. As of June 30th, there was short interest totaling 234,995 shares, an increase of 90.3% from the June 15th total of 123,461 shares. Currently, 127.0% of the company’s stock are short sold. Based on an average daily volume of 13,939,399 shares, the short-interest ratio is presently 0.0 days.

Analyst Ratings Changes

A number of analysts have weighed in on PFSA shares. Wall Street Zen upgraded Profusa from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Profusa in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Profusa currently has a consensus rating of “Sell”.

Profusa Stock Down 2.4%

Profusa stock traded down $0.04 during mid-day trading on Friday, hitting $1.81. The company had a trading volume of 43,005 shares, compared to its average volume of 162,869. Profusa has a 1 year low of $1.69 and a 1 year high of $4,162.50. The business has a fifty day moving average of $6.27 and a 200 day moving average of $51.02. The stock has a market cap of $344,850.00, a price-to-earnings ratio of -0.00 and a beta of 0.46.

Profusa (NASDAQ:PFSA) last issued its quarterly earnings data on Wednesday, April 15th. The company reported $2,231.25 earnings per share for the quarter.

About Profusa

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.